MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 3, 2005; DOI: 10.1124/mol.105.014043


0026-895X/05/6803-769-778$20.00
Mol Pharmacol 68:769-778, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.014043v1
68/3/769    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.-P.
Right arrow Articles by Ellis, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.-P.
Right arrow Articles by Ellis, J.

Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide

Xi-Ping Huang, Stefanie Prilla, Klaus Mohr, and John Ellis

Departments of Psychiatry and Pharmacology, Hershey Medical Center, Penn State University College of Medicine, Hershey, Pennsylvania (X.-P.H., J.E.); and Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Bonn, Bonn, Germany (S.P., K.M.)

The structurally divergent agents gallamine and hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide (W84) are known to interact competitively at a common allosteric site on muscarinic receptors. Previous studies reported that the M2 selectivity of gallamine depended largely on the EDGE (172-175) sequence in the second outer loop (o2) and on 419Asn near the junction of o3 and the seventh transmembrane domain (TM7), whereas the selectivity of W84 depended on nearby residues 177Tyr and 423Thr. However, it has so far proven difficult to confer the high sensitivity for allosteric modulation of the M2 subtype onto the weakly sensitive M5 subtype by substituting these key residues. We now have found that M2 423Thr, not 419Asn, is the dominant residue in the o3/TM7 region for gallamine's high potency, although 419Asn can substitute for 423Thr in some contexts; in contrast, the presence of 419Asn reduces the potency of W84 in every context we have studied. In addition, the orientation of 177Tyr is crucial to high sensitivity toward W84, and it seems that the proline residue at position 179 in M5 (corresponding to M2 172Glu) may interfere with that orientation. Consistent with these observations, a mutant M5 receptor with these three key mutations, M5P179E, Q184Y, and H478T, showed dramatically increased sensitivity for W84 (>100-fold), compared with the wild-type M5 receptor. This same mutant receptor approached M2 sensitivity toward gallamine. Thus, gallamine and W84 derive high potency from the same receptor domains (epitopes in o2 and near the junction between o3 and TM7), even though these allosteric agents have quite different structures.


Received for publication April 24, 2005.

Accepted for publication June 3, 2005.

Address correspondence to: Dr. John Ellis, Department of Psychiatry, H073, Hershey Medical Center, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033. E-mail: JohnEllis{at}psu.edu




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
W. Y. Chan, D. L. McKinzie, S. Bose, S. N. Mitchell, J. M. Witkin, R. C. Thompson, A. Christopoulos, S. Lazareno, N. J. M. Birdsall, F. P. Bymaster, et al.
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
PNAS, August 5, 2008; 105(31): 10978 - 10983.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Jager, C. Schmalenbach, S. Prilla, J. Schrobang, A. Kebig, M. Sennwitz, E. Heller, C. Trankle, U. Holzgrabe, H.-D. Holtje, et al.
Allosteric Small Molecules Unveil a Role of an Extracellular E2/Transmembrane Helix 7 Junction for G Protein-coupled Receptor Activation
J. Biol. Chem., November 30, 2007; 282(48): 34968 - 34976.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. T. May, V. A. Avlani, C. J. Langmead, H. J. Herdon, M. D. Wood, P. M. Sexton, and A. Christopoulos
Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors
Mol. Pharmacol., August 1, 2007; 72(2): 463 - 476.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X.-P. Huang and J. Ellis
Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands
Mol. Pharmacol., March 1, 2007; 71(3): 759 - 768.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Prilla, J. Schrobang, J. Ellis, H.-D. Holtje, and K. Mohr
Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity
Mol. Pharmacol., July 1, 2006; 70(1): 181 - 193.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics